Denosumab, raloxifene, romosozumab and teriparatide to prevent osteoporotic fragility fractures: a systematic review and economic evaluation

Review (52 RCTs for clinical and 51 for economic evaluation) found non-bisphosphonates are effective in preventing fragility fractures, but incremental cost-effectiveness ratios are greater than the commonly applied threshold of £20,000–30,000 per quality-adjusted life-year.


National Institute for Health Research